On September 14, 2023 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), reported that renowned dermato- oncology key opinion leader and study investigator, Professor Rudolf Stadler, University Hospital Johannes Wesling, Minden, Germany, will give an oral presentation on the findings from his RESMAIN study investigating the efficacy of resminostat as a maintenance treatment for cutaneous T-cell lymphoma, at the EORTC Cutaneous Lymphoma Tumor Group Annual Meeting at the Leiden University Medical Center, the Netherlands, September 21-23 (Press release, 4SC, SEP 14, 2023, https://www.pressetext.com/news/20230915007 [SID1234635167]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: RESMAIN: Results of a multicenter, randomized, double blind, placebo controlled trial to evaluate resminostat for maintenance treatment in advanced stage Mycosis fungoides or Sézary syndrome
Presenting Author: Professor Rudolf Stadler, University Hospital Johannes Wesling, Ruhr University Bochum, Minden, Germany
Date and Time: Saturday September 23rd, 9:10am CET
Location: Leiden University Medical Center, the Netherlands, Room: O-143
4SC will host a webinar to present an analysis of the findings showcased at the EORTC CLTG Annual Meeting on Wednesday 4th October. Clinical experts, Professor Rudolf Stadler and Professor Julia Scarisbrick, will discuss the results and there will be the opportunity to ask questions during a Q&A session moderated by 4SC’s Chief Executive Officer, Jason Loveridge.
Title: Presentation by Professor Rudolf Stadler and Professor Julia Scarisbrick on recent new positive data from the RESMAIN study
Date and Time: Wednesday 4th October, 3.00pm CET
Register and submit questions:View Source
Jason Loveridge, Ph.D., Chief Executive Officer of 4SC, commented: "Our pivotal RESMAIN study was conducted at more than 50 clinical centers across Europe and by Yakult Honsha in Japan, investigating the efficacy of resminostat as a maintenance treatment for cutaneous T -cell lymphoma. Resminostat is an orally administered class I, IIb and IV histone deacetylase (HDAC) inhibitor which is well tolerated and can inhibit tumor growth and proliferation, cause tumor regression, and strengthen the body’s immune response to cancer. We look forward to presenting the results of the trial for the first time during this prestigious conference and our live webinar in October."